Development and optimization of recent technologies, such as multimer staining for flow cytometry analysis, offer potential in characterizing COVID-19-specific HLA class I and II CD8+ and CD4+ T cell responses and eventually correlate their frequency with disease severity and outcome. This evidence concerns the gene CD8A and COVID-19.